Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
Clinical trial NCT00489970 · COMPLETED
Trial details
- NCT number
- NCT00489970
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2007-06-01
- Primary completion
- 2011-09-01
- Enrollment
- 1954
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.